S&P TSX Capped Composite...

US Dollar vs CAD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

NVS Novartis AG

107.22

0.00 (0.00%)

Jul 18 2024 - Closed

Delayed by 15 minutes

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Article too big to display. Click here to view on the SEC website

Novartis (NYSE:NVS)
Historical Stock Chart
From Jun 2024 to Jul 2024

Click Here for more Novartis Charts.

Novartis (NYSE:NVS)
Historical Stock Chart
From Jul 2023 to Jul 2024

Click Here for more Novartis Charts.

Novartis AG News

Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
Thursday 18 July 2024 (11 hours ago) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Thursday 18 July 2024 (21 hours ago) • Edgar (US Regulatory)

TSMC Net Profit Hits $7.6B; Nokia Sees 32% Decline in Operating Profit; Novartis Boosts Outlook After Profit Surge
Thursday 18 July 2024 (21 hours ago) • IH Market News

Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
Thursday 11 July 2024 (1 week ago) • Edgar (US Regulatory)

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
Monday 17 June 2024 (1 month ago) • Edgar (US Regulatory)

Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio
Saturday 25 May 2024 (2 months ago) • PR Newswire (US)

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo
Saturday 25 May 2024 (2 months ago) • PR Newswire (US)

Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
Friday 24 May 2024 (2 months ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Wednesday 22 May 2024 (2 months ago) • Edgar (US Regulatory)

Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
Tuesday 7 May 2024 (2 months ago) • GlobeNewswire Inc.

Apple Loses Market Share in China, GM Surges in Pre-Market Following Upward Revisions for 2024 Projections, and More News
Tuesday 23 April 2024 (3 months ago) • IH Market News

New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
Monday 15 April 2024 (3 months ago) • PR Newswire (US)

More Novartis AG News Articles

Virexit Technologies (PK)

1812 Brewing (PK)

Ubiquitech Software (PK)

Net Savings Link (PK)

AMC Entertainment

Yuenglings Ice Cream (PK)

Voip Pal Com (QB)

Cann American (CE)

Ilustrato Pictures (PK)

Enzolytics (PK)

KAT Exploration (CE)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions